Cowen maintained an Outperform rating on Aquinox Pharmaceutical (NASDAQ: AQXP), and cut the price target to $23.00 (from $24.00), following ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst EPS Change Analyst PT Change

Needham & Company Keeps Aquinox Pharma (AQXP) at 'Buy'; Failure of AQX-1125 in Atopic Dermatitis Won't Impact ModelNovember 3, 2015 9:48 AM Pre-Open Stock Movers 11/03: (SALE) (KING) (AEO) Higher; (QLYS) (S) (FIT) Lower (more...)November 3, 2015 9:27 AM Aquinox Pharma's (AQXP) Phase 2 KINSHIP Trial With AQX-1125 Fails to Demonstrate EfficacyNovember 3, 2015 6:36 AM Aquinox Pharmaceuticals Announces Results From Phase 2 KINSHIP Trial With AQX-1125 in Patients With Atopic DermatitisNovember 2, 2015 8:15 PM Aquinox Pharmaceuticals Announces Results From Phase 2 KINSHIP Trial With AQX-1125 in Patients With Atopic DermatitisNovember 2, 2015 8:15 PM